Dactinomycin FDA Link Generic

A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

Also Known As:

Actinomycin; Actinomycin D; Cosmegen; Cosmegen Lyovac; Lyovac-Cosmegen; Lyovac Cosmegen; Lyovac, Cosmegen; LyovacCosmegen; Meractinomycin

Pharmalogical Action Categories:

Anti-Bacterial Agents
Antibiotics, Antineoplastic
Nucleic Acid Synthesis Inhibitors
Protein Synthesis Inhibitors

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Dactinomycin: 2073
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Dactinomycin: 2073
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Dactinomycin: 2073

Kingdom Children's Cancer Study Group Pharmacology Working Group Selected Research

Kingdom Children's Cancer Study Group Pharmacology Working Group Research Topics

Disease

Drug/Important Bio-Agent (IBA)